Trial Profile
An open label, randomized, phase III trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus CaLmette-Guerin) bladder instillation in BCG-naive patients with high-risk non-muscle invasive Bladder cANcer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; BCG
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms ALBAN
- 05 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 24 May 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2024.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.